HOOKIPA Pharma Provides Update on Business Priorities and On

HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development...

Related Keywords

Vienna , Wien , Austria , Joern Aldag , Michael Kaiser , Pharma Inc , Exchange Commission , Nasdaq , Investigational New Drug , Chief Executive Officer , Disease Programs , Human Papillomavirus , Private Securities Litigation Reform Act , Roche Collaboration Agreement , Markets ,